ATE449859T1 - Virusvektor zur gentherapie - Google Patents

Virusvektor zur gentherapie

Info

Publication number
ATE449859T1
ATE449859T1 AT02727029T AT02727029T ATE449859T1 AT E449859 T1 ATE449859 T1 AT E449859T1 AT 02727029 T AT02727029 T AT 02727029T AT 02727029 T AT02727029 T AT 02727029T AT E449859 T1 ATE449859 T1 AT E449859T1
Authority
AT
Austria
Prior art keywords
gene therapy
virus vector
infectivity
type
adenovirus
Prior art date
Application number
AT02727029T
Other languages
English (en)
Inventor
Goeran Wadell
Ya-Fang Mei
Anna Segerman
Johan Skog
Kristina Lindman
Original Assignee
Goeran Wadell
Ya-Fang Mei
Anna Segerman
Johan Skog
Kristina Lindman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26655363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE449859(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0100035A external-priority patent/SE0100035D0/xx
Application filed by Goeran Wadell, Ya-Fang Mei, Anna Segerman, Johan Skog, Kristina Lindman filed Critical Goeran Wadell
Application granted granted Critical
Publication of ATE449859T1 publication Critical patent/ATE449859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02727029T 2001-01-04 2002-01-04 Virusvektor zur gentherapie ATE449859T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100035A SE0100035D0 (sv) 2001-01-04 2001-01-04 Viral vectors for gene therapy
US26035801P 2001-01-08 2001-01-08
PCT/SE2002/000013 WO2002053759A1 (en) 2001-01-04 2002-01-04 Viral vector for gene therapy

Publications (1)

Publication Number Publication Date
ATE449859T1 true ATE449859T1 (de) 2009-12-15

Family

ID=26655363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727029T ATE449859T1 (de) 2001-01-04 2002-01-04 Virusvektor zur gentherapie

Country Status (6)

Country Link
US (1) US7459153B2 (de)
EP (1) EP1348030B1 (de)
AT (1) ATE449859T1 (de)
AU (1) AU2002217721A1 (de)
DE (1) DE60234496D1 (de)
WO (1) WO2002053759A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
EP1553983A2 (de) 2002-10-23 2005-07-20 Crucell Holland B.V. Einstellung für rekombinante adenovirus-basierte impfstoffe
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1646717A4 (de) * 2003-07-18 2006-12-20 Onyx Pharma Inc Adenovirus-untergruppe-b-vektoren zur behandlung von krankheiten
ES2358204T3 (es) * 2004-05-26 2011-05-06 Bayer Schering Pharma Aktiengesellschaft Adenovirus quiméricos para uso en el tratamiento del cáncer.
JP5448840B2 (ja) * 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
WO2011032100A1 (en) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
EP2486137B1 (de) * 2009-10-05 2018-05-30 Ya-Fang Mei Auf ad11p beruhende replikations-kompetente virale vektoren
US9572893B2 (en) 2012-11-07 2017-02-21 Council Of Scientific And Industrial Research Nanocomplex containing cationic peptide for biomolecule delivery
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
WO1999019500A1 (en) * 1997-10-10 1999-04-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery
ATE519854T1 (de) * 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
US6524572B1 (en) * 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy

Also Published As

Publication number Publication date
US20040136958A1 (en) 2004-07-15
EP1348030A1 (de) 2003-10-01
EP1348030B1 (de) 2009-11-25
WO2002053759A1 (en) 2002-07-11
AU2002217721A8 (en) 2007-12-06
DE60234496D1 (de) 2010-01-07
AU2002217721A1 (en) 2002-07-16
WO2002053759A9 (en) 2007-10-11
US7459153B2 (en) 2008-12-02

Similar Documents

Publication Publication Date Title
DE60234496D1 (de) Virusvektor zur gentherapie
Lubotzky et al. Explicit constructions of Ramanujan complexes of type Ad
WO2004063362A3 (en) Cell cycle progression proteins
IS7896A (is) Latar á lifrarbólgu C vírus ríbósakjarnsýru-háðu ríbósakjarnsýru liðunarensími, og samsetningar og meðferðir sem nota þá.
GB0303188D0 (en) An herpes simplex virus complex
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
GB2448281A (en) Cross connect terminal block
WO2004013307A3 (en) Compounds for targeting hepatocytes
AU308383S (en) Point of sale terminal
AU306520S (en) Point of sale terminal
ATE393371T1 (de) Behälter für grosskalibrige munition
ATE373081T1 (de) Zelllinie
WO2002079419A3 (en) Identifying and characterizing genes
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
AU306519S (en) Point of sale terminal
CA2529001A1 (en) Binding peptides: methods for their generation and use
WO2002050304A3 (en) Oncolytic virus
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
DE50113417D1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
Lobo Primary lead and zinc boosted in India
WO2003004610A3 (en) Hsst and angiogenesis
TW200628798A (en) Testing probe
Stephens Performance Based Qualification: A Way to Increase NDT Reliability
Pearson The short straw.
ES1046984U (es) Multicuchillo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties